| 영문 | fibrin | 한글 | 섬유소 |
|---|---|---|---|
| 설명 | 피가 굳을 때 섬유소에 트롬빈이 작용하여 생기는 섬유 같은 단백질. 무색이나 엷은 황색을 띤 고체로, 물에 잘 녹지 않으며 혈구와 엉키어 피를 굳게 하여 출혈을 그치게 한다. |
||
| 영문 | rheumatoid factor | 한글 | 류마티스 인자 |
|---|---|---|---|
| 설명 | IgG의 Fc부위에 있는 항원결정인자에 대한 항체로서 전형적인 또는 확실한 류마티스관절염(rheumatoid arthritis) 환자의 80%에서 발견된다. 류마티스 인자는 IgM, IgG, IgA중 하나가 될 수 있으나 주로 IgM이다. 소아류마티스관절염(juvenile rheumatoid arthritis: 소아기에 발생하는 류마티스관절염)을 비롯한, 다른 결합조직병이나 감염병에도 나타날 수 있다 |
||
| 영문 | growth factor | 한글 | 성장인자 |
|---|---|---|---|
| 설명 | 세포의 분화 및 성장에 관여하는 단백질. 성장인자는 정상 세포주기에 필수적이기 때문에 동물의 생명에 중대한 요소가 된다. 무엇보다도 성장인자는 태아의 발육을 조정하고 조직의 유지 및 보수에 중대한 역할을 하며, 혈구의 생성을 자극한다. 또한 암의 진행과정에도 관여한다. |
||
| 영문 | risk factor | 한글 | 위험인자 |
|---|---|---|---|
| 설명 | 국제방사선방호위원회(ICRP)가 1977년 권고에서 방사선방호의 목적으로 채택한 지수로, 단위선량(1 Sv)당 확률적 영향의 발생확률을 추정하여 나타낸 것이다. 생식선 선량에 대한 유전적영향의 발생률(4×10－3/Sv)이나 적색골수선량에 대한 백혈병 발생률(2×10－3/Sv)등 외에 뼈, 허파, 갑상샘, 젖샘, 기타 조직의 위험지수를 측정하여, 확률적 영향의 전신에 있어서 치사위험지수의 합계를 16.5×10－3/Sv로 하였다. 그후 ICRP는 1990년 권고에서 대상이 되는 조직과 장기를 추가하고, 수치 개정을 하면서 명칭도 각목적확률지수라고하였다. 이 권고에 의하면, 치사적 확률적 영향의 확률지수의 합계는, 일반인에 있어 60.0×10－3/Sv이다. |
||
| FSF | Fibrin Stabilizing Factor(Factor XIII) |
|---|---|
| MSA | major serologic antigen; male-specific antigen; mannitol salt agar; Medical Services Administration;... |
| FSF | fibrin stabilizing factor; front surface fluorescence |
| CF | calcaneal fibular [ligament]; calcium leucovorin; calf blood flow; calibration factor; cancer-free; ... |
| SFC | soluble fibrin complex; soluble fibrin-fibrinogen complex; spinal fluid count |
| MSP | manganese stabilizing protein |
|---|---|
| FDP | Fibrin Degradation Product |
| FbDP | Fibrin Degradation Products |
| FS | Fibrin Sealant |
| FG | Fibrin glue |
IGF-II : insulin like growth factor-II의 약자. 많은 장기와 조직에 작용하여 단백 합성과 DNA, RNA의 합성을 증가시켜 세포의 수와 양을 증가
| fibrin-stabilizing factor | <chemical> Fibrin stabilizing factor. It is a glycoprotein activated by thrombin in the presence of calcium to form factor xiiia. Factor xiii is found evenly distributed between plasma and platelets. Its function is to stabilise the formation of the fibrin polymer (clot) which culminates the coagulation cascade. Chemical name: Blood-coagulation factor XIII (12 Dec 1998) |
|---|---|
| stabilizing circumferential clasp arm | An arm that is relatively rigid and embraces the height of contour of the tooth. (05 Mar 2000) |
| stabilizing fulcrum line | An imaginary line connecting occlusal rests, around which line the denture tends to rotate under masticatory force. (05 Mar 2000) |
| human fibrin foam | A dry artificial sponge of human fibrin prepared by clotting with thrombin a foam of a solution of human fibrinogen; the clotted foam is dried from the frozen state and heated; used as a topical anticoagulant. (05 Mar 2000) |
| fibrin | <protein> The insoluble protein formed from fibrinogen by the proteolytic action of thrombin during normal clotting of blood. Fibrin forms the essential portion of the blood clot. (12 Nov 1997) |
| fibrin calculus | A urinary calculus formed largely from fibrinogen in blood. (05 Mar 2000) |
| fibrin degradation products | <haematology, investigation> A test that measures fibrin degradation products which result from the dissolution of a blood clot. Normal value is less than 10 mcg/ml (micrograms per millilitre). They may be increased in conditions such as burns, placental abruption, heart disease, DIC, after massive blood transfusion, hypoxia, intrauterine foetal death, portacaval shunt, leukaemia, transfusion reaction, transplant rejection, sepsis, renal failure and preeclampsia. Acronym: FDP (23 Sep 2002) |
| fibrin destabilase | <enzyme> Hydrolyses the epsilon-(gamma-glutamyl)-lysine bonds of stabilised fibrin Pharmacological action: fibrinolytic agents Registry number: EC 3.4.99.- Synonym: destabilase (26 Jun 1999) |
| fibrin fibrinogen degradation products | <chemical> Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. Fdp and their complexes profoundly impair the haemostatic process and are a major cause of haemorrhage in intravascular coagulation and fibrinolysis. Pharmacological action: antithrombins. (12 Dec 1998) |
| fibrin foam | <chemical> A dry artificial sterile sponge of fibrin prepared by clotting with thrombin a foam or solution of fibrinogen. It is used in conjunction with thrombin as a haemostatic in surgery at sites where bleeding cannot be controlled by more common methods. Pharmacological action: haemostatics, tissue adhesives. (12 Dec 1998) |
| fibrinogen-fibrin conversion syndrome | <syndrome> A syndrome characterised by hypofibrinogenaemia with incoagulable blood; it may be seen in abruptio placentae, prolonged retention of a dead foetus in an Rh-isosensitised mother, haemolytic blood reactions, bilateral renal cortical necrosis, and cases of trauma. (05 Mar 2000) |
| fibrin thrombus | A thrombus formed by repeated deposits of fibrin from the circulating blood; it usually does not completely occlude the vessel. (05 Mar 2000) |
| fibrin tissue adhesive | <chemical> An autologous or commercial tissue adhesive containing fibrinogen and thrombin. The commercial product is a two component system from human plasma that contains more than fibrinogen and thrombin. The first component contains highly concentrated fibrinogen, factor viii, fibronectin, and traces of other plasma proteins. The second component contains thrombin, calcium chloride, and antifibrinolytic agent such as aprotinin. Mixing of the two components promotes clotting and the formation and cross-linking of fibrin. The tissue adhesive is used for tissue sealing, haemostasis, and wound healing. Pharmacological action: haemostatics, tissue adhesives. (12 Dec 1998) |
| accelerator factor | <chemical> Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor v accomplishes this by forming a complex with factor xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor v leads to owren's disease. Chemical name: Blood-coagulation factor V (12 Dec 1998) |
| acetate replacement factor | <biochemistry> 1,2 dithiolane 3 valeric acid. Regarded as a coenzyme in the oxoglutarate dehydrogenase complex of the citric acid cycle. Involved generally in oxidative decarboxylations of _ keto acids. A growth factor for some organisms. (18 Nov 1997) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|